{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T13:04:10Z","timestamp":1770815050394,"version":"3.50.1"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2015,7,22]],"date-time":"2015-07-22T00:00:00Z","timestamp":1437523200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1007\/s00228-015-1906-z","type":"journal-article","created":{"date-parts":[[2015,7,21]],"date-time":"2015-07-21T01:53:07Z","timestamp":1437443587000},"page":"1185-1196","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Ethylphenidate: availability, patterns of use, and acute effects of this novel psychoactive substance"],"prefix":"10.1007","volume":"71","author":[{"given":"James H.","family":"Ho","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George P.","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John R. H.","family":"Archer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul I.","family":"Dargan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,7,22]]},"reference":[{"key":"1906_CR1","unstructured":"Advisory Council on the Misuse of Drugs (ACMD) (2011) Consideration of the novel psychoactive substances (\u2018Legal Highs\u2019). https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/119139\/acmdnps2011.pdf . Accessed 12 February 2015"},{"key":"1906_CR2","volume-title":"Novel psychoactive substances: classification, pharmacology and toxicology","author":"PI Dargan","year":"2013","unstructured":"Dargan PI, Wood DM (2013) Novel psychoactive substances: classification, pharmacology and toxicology. Elsevier, Amsterdam"},{"key":"1906_CR3","unstructured":"EMCDDA. 2013 Europol 2013 Annual Report on the implementation of Council Decision. http:\/\/www.emcdda.europa.eu\/attachements.cfm\/att_229598_EN_TDAN14001ENN.pdf . Accessed 12 February 2015"},{"issue":"1","key":"1906_CR4","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3109\/15563650.2011.645952","volume":"50","author":"S Gibbons","year":"2012","unstructured":"Gibbons S (2012) \u2018Legal highs\u2019\u2014novel and emerging psychoactive drugs: a chemical overview for the toxicologist. Clin Toxicol (Phila) 50(1):15\u201324. doi: 10.3109\/15563650.2011.645952","journal-title":"Clin Toxicol (Phila)"},{"issue":"6","key":"1906_CR5","doi-asserted-by":"crossref","first-page":"318","DOI":"10.9740\/mhc.n183949","volume":"3","author":"JS Markowitz","year":"2013","unstructured":"Markowitz JS, Patrick KS (2013) Ethylphenidate: from biomarker to designer drug. Mental Health Clinician 3(6):318\u2013320. doi: 10.9740\/mhc.n183949","journal-title":"Mental Health Clinician"},{"issue":"12","key":"1906_CR6","doi-asserted-by":"crossref","first-page":"3834","DOI":"10.1002\/jps.24202","volume":"103","author":"KS Patrick","year":"2014","unstructured":"Patrick KS, Corbin TR, Murphy CE (2014) Ethylphenidate as a selective dopaminergic agonist and methylphenidate-ethanol transesterification biomarker. J Pharm Sci 103(12):3834\u20133842. doi: 10.1002\/jps.24202","journal-title":"J Pharm Sci"},{"key":"1906_CR7","author":"PK Parekh","year":"2015","unstructured":"Parekh PK, Ozburn AR, McClung CA (2015) Circadian clock genes: effects on dopamine, reward and addiction. Alcohol. doi: 10.1016\/j.alcohol.2014.09.034","journal-title":"Alcohol"},{"key":"1906_CR8","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/jps.2600500611","volume":"50","author":"PS Portoghese","year":"1961","unstructured":"Portoghese PS, Malspeis L (1961) Relative hydrolytic rates of certain alkyl (b) dl-alpha-(2-piperidyl)-phenylacetates. J Pharm Sci 50:494\u2013501","journal-title":"J Pharm Sci"},{"issue":"10","key":"1906_CR9","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/bms.1200061003","volume":"6","author":"CR Iden","year":"1979","unstructured":"Iden CR, Hungund BL (1979) A chemical ionization selected ion monitoring assay for methylphenidate and ritalinic acid. Biomed Mass Spectrom 6(10):422\u2013426. doi: 10.1002\/bms.1200061003","journal-title":"Biomed Mass Spectrom"},{"issue":"6","key":"1906_CR10","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0009-9120(80)80007-5","volume":"13","author":"YM Chan","year":"1980","unstructured":"Chan YM, Soldin SJ, Swanson JM (1980) Gas chromatographic\/mass spectrometric analysis of methylphenidate (Ritalin) in serum. Clin Biochem 13(6):266\u2013272","journal-title":"Clin Biochem"},{"issue":"12","key":"1906_CR11","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1021\/js970072x","volume":"86","author":"JA Bourland","year":"1997","unstructured":"Bourland JA, Martin DK, Mayersohn M (1997) Carboxylesterase-mediated transesterification of meperidine (Demerol) and methylphenidate (Ritalin) in the presence of [2H6]ethanol: preliminary in vitro findings using a rat liver preparation. J Pharm Sci 86(12):1494\u20131496. doi: 10.1021\/js970072x","journal-title":"J Pharm Sci"},{"issue":"4","key":"1906_CR12","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/00004714-199908000-00013","volume":"19","author":"JS Markowitz","year":"1999","unstructured":"Markowitz JS, Logan BK, Diamond F, Patrick KS (1999) Detection of the novel metabolite ethylphenidate after methylphenidate overdose with alcohol coingestion. J Clin Psychopharmacol 19(4):362\u2013366","journal-title":"J Clin Psychopharmacol"},{"issue":"6","key":"1906_CR13","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S0090-9556(24)15139-2","volume":"28","author":"JS Markowitz","year":"2000","unstructured":"Markowitz JS, DeVane CL, Boulton DW, et al (2000) Ethylphenidate formation in human subjects after the administration of a single dose of methylphenidate and ethanol. Drug Metab Dispos 28(6):620\u2013624","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"1906_CR14","first-page":"238","volume":"60","author":"M Koehm","year":"2010","unstructured":"Koehm M, Kauert GF, Toennes SW (2010) Influence of ethanol on the pharmacokinetics of methylphenidate\u2019s metabolites ritalinic acid and ethylphenidate. Arzneimittelforschung 60(5):238\u2013244","journal-title":"Arzneimittelforschung"},{"issue":"7","key":"1906_CR15","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1002\/jps.22476","volume":"100","author":"GH Bell","year":"2011","unstructured":"Bell GH, Novak AJ, Griffin 3rd WC, Patrick KS (2011) Transdermal and oral dl-methylphenidate-ethanol interactions in C57BL\/6J mice: transesterification to ethylphenidate and elevation of d-methylphenidate concentrations. J Pharm Sci 100(7):2966\u20132978. doi: 10.1002\/jps.22476","journal-title":"J Pharm Sci"},{"key":"1906_CR16","doi-asserted-by":"crossref","unstructured":"Epstein T, Patsopoulos NA, Weiser M (2014) Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database Syst Rev 9(CD005041. 10.1002\/14651858.CD005041.pub2","DOI":"10.1002\/14651858.CD005041.pub2"},{"key":"1906_CR17","unstructured":"Bluelight. Ethylphenidate\u2014anyone tried it yet?. http:\/\/www.bluelight.org\/vb\/archive\/index.php\/t-520608.htm . Accessed 13 February 2015"},{"key":"1906_CR18","unstructured":"EMCDDA. (2011) Europol 2011 Annual Report on the implementation of Council Decision. https:\/\/www.europol.europa.eu\/sites\/default\/files\/publications\/emcddaeuropol_annual_report_2011_2012_final.pdf . Accessed 12 February 2015"},{"key":"1906_CR19","first-page":"9","volume":"9","author":"C Soussan","year":"2015","unstructured":"Soussan C, Kjellgren A (2015) Chasing the high\u201d\u2014experiences of ethylphenidate as described on international Internet forums. Subst Abuse 9:9\u201316. doi: 10.4137\/SART.S22495","journal-title":"Subst Abuse"},{"key":"1906_CR20","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.forsciint.2014.07.017","volume":"243","author":"J Krueger","year":"2014","unstructured":"Krueger J, Sachs H, Musshoff F, et al (2014) First detection of ethylphenidate in human fatalities after ethylphenidate intake. Forensic Sci Int 243:126\u2013129. doi: 10.1016\/j.forsciint.2014.07.017","journal-title":"Forensic Sci Int"},{"key":"1906_CR21","doi-asserted-by":"crossref","unstructured":"Bailey GP, Ho JH, Hudson S et al (2015) Nopaine no gain: recreational ethylphenidate toxicity. Clin Toxicol (Phila) In Press","DOI":"10.3109\/15563650.2015.1033062"},{"key":"1906_CR22","unstructured":"EAPCCT (2010) Abstracts of the 2010 International Congress of the European Association of Poisons Centres an d Clinical Toxicologists, 11\u201314 May 2010, Bordeaux, France. Clin Toxicol (Phila) 48(240\u2013318. 10.3109\/15563651003740240"},{"key":"1906_CR23","unstructured":"NACCT (2010) NACCT 2010 abstracts. Clin Toxicol (Phila) 48(604\u2013667. 10.3109\/15563650.2010.493290"},{"key":"1906_CR24","unstructured":"EAPCCT (2011) Abstracts of the 2011 International Congress of the European Association of Poisons Centres and Clinical Toxicologists, 24\u201327 May 2011, Dubrovnik, Croatia. Clin Toxicol (Phila) 49(197\u2013269. 10.3109\/15563650.2011.568269"},{"key":"1906_CR25","unstructured":"NACCT (2011) 2011 Annual Meeting of the North American Congress of Clinical Toxicology (NACCT). Clin Toxicol (Phila) 49(515\u2013627. 10.3109\/15563650.2011.598695"},{"key":"1906_CR26","doi-asserted-by":"crossref","unstructured":"EAPCCT (2012) Abstracts of the 2012 International Congress of the European Association of Poisons Centres and Clinical Toxicologists, 25 May\u20131 June 2012, London, UK Clin Toxicol (Phila) 50(273\u2013366. 10.3109\/15563650.2012.669957","DOI":"10.3109\/15563650.2012.669957"},{"key":"1906_CR27","doi-asserted-by":"crossref","first-page":"574","DOI":"10.3109\/15563650.2012.700015","volume":"50","author":"NACCT","year":"2012","unstructured":"NACCT (2012) 2012 Annual Meeting of the North American Congress of Clinical Toxicology (NACCT) October 1\u20136, 2012 Las Vegas, NV, USA. Clin Toxicol (Phila) 50:574\u2013720. doi: 10.3109\/15563650.2012.700015","journal-title":"Clin Toxicol (Phila)"},{"key":"1906_CR28","doi-asserted-by":"crossref","first-page":"252","DOI":"10.3109\/15563650.2013.785188","volume":"51","author":"EAPCCT","year":"2013","unstructured":"EAPCCT (2013) XXXIII International Congress of the European Association of Poisons Centres and Clinical Toxicologists (EAPCCT) 28\u201331 May 2013, Copenhagen, Denmark. Clin Toxicol (Phila) 51:252\u2013378. doi: 10.3109\/15563650.2013.785188","journal-title":"Clin Toxicol (Phila)"},{"key":"1906_CR29","doi-asserted-by":"crossref","first-page":"575","DOI":"10.3109\/15563650.2013.817658","volume":"51","author":"NACCT","year":"2013","unstructured":"NACCT (2013) 2013 Annual Meeting of the North American Congress of Clinical Toxicology (NACCT). Clin Toxicol (Phila) 51:575\u2013724. doi: 10.3109\/15563650.2013.817658","journal-title":"Clin Toxicol (Phila)"},{"key":"1906_CR30","unstructured":"EAPCCT (2014) XXXIV International Congress of the European Association of Poisons Centres and Clinical Toxicologists (EAPCCT) 27\u201330 May 2014, Brussels, Belgium. Clin Toxicol (Phila) 52(295\u2013443. 10.3109\/15563650.2014.906213"},{"key":"1906_CR31","doi-asserted-by":"crossref","first-page":"682","DOI":"10.3109\/15563650.2014.940163","volume":"52","author":"NACCT","year":"2014","unstructured":"NACCT (2014) 2014 Annual Meeting of the North American Congress of Clinical Toxicology (NACCT). Clin Toxicol (Phila) 52:682\u2013818. doi: 10.3109\/15563650.2014.940163","journal-title":"Clin Toxicol (Phila)"},{"issue":"3","key":"1906_CR32","doi-asserted-by":"crossref","first-page":"330","DOI":"10.3109\/10826080903443628","volume":"45","author":"J Hillebrand","year":"2010","unstructured":"Hillebrand J, Olszewski D, Sedefov R (2010) Legal highs on the Internet. Subst Use Misuse 45(3):330\u2013340. doi: 10.3109\/10826080903443628","journal-title":"Subst Use Misuse"},{"key":"1906_CR33","unstructured":"European Commission. Financial programming and budget.. http:\/\/ec.europa.eu\/budget\/contracts_grants\/info_contracts\/inforeuro\/inforeuro_en.cfm . Accessed 12 February 2015"},{"key":"1906_CR34","unstructured":"Secretary\u2019s Advisory Committee on Human Research Protections (SACHRP) (2013) Considerations and recommendations concerning Internet research and human subjects research regulations, with revisions. http:\/\/www.hhs.gov\/ohrp\/sachrp\/commsec\/attachmentbsecletter20.pdf . Accessed 30 June 2015"},{"issue":"4","key":"1906_CR35","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1097\/JCP.0000000000000360","volume":"35","author":"B Pignon","year":"2015","unstructured":"Pignon B, Muyssen A, Deheul S, Cottencin O, Rolland B (2015) Dependence on Internet-purchased ethylphenidate. J Clin Psychopharmacol 35(4):472\u2013473. doi: 10.1097\/JCP.0000000000000360","journal-title":"J Clin Psychopharmacol"},{"key":"1906_CR36","volume-title":"XXXIII International Congress of the European Association of Poisons Centres and Clinical Toxicologists (EAPCCT)","author":"M B\u00e4ckberg","year":"2012","unstructured":"B\u00e4ckberg M, Westerbergh J, Al-Saffar Y, Lindeman E, Helander A (2012) Trends in intoxications of novel psychoactive substances in Sweden during. In: XXXIII International Congress of the European Association of Poisons Centres and Clinical Toxicologists (EAPCCT). Copenhagen, Denmark"},{"key":"1906_CR37","first-page":"eA292","volume-title":"Systematic approach to legal highs monitoring as part of drugs of abuse screening with LC-MSTof as a foundation 3rd EFLM-UEMS Congress - Laboratory Medicine at the Clinical Interface","author":"L Ford","year":"2014","unstructured":"Ford L, Berg J (2014) Systematic approach to legal highs monitoring as part of drugs of abuse screening with LC-MSTof as a foundation 3rd EFLM-UEMS Congress - Laboratory Medicine at the Clinical Interface. Liverpool, United Kingdom, pp. eA292\u2013eA293"},{"key":"1906_CR38","unstructured":"UK Legal Highs Forum. Ethylphenidate\/ethylcaine super detailed report. http:\/\/www.legalhighsforum.com\/showthread.php?17351-Ethylphenidate-Ethylcaine-SUPER-DETAILED-Report . Accessed 13 February 2015"},{"key":"1906_CR39","unstructured":"The Trip Report. [300\u00a0mg] Ethylphenidate review. http:\/\/the-tripreport.com\/site\/tripreport\/300mg-ethylphenidate-review\/ . Accessed 13 February 2015"},{"key":"1906_CR40","unstructured":"Chems R Us. Ethylphenidate trip report. http:\/\/www.chemsrus.com\/forum\/14-trip-reports\/4098-ethylphenidate-trip-report . Accessed 13 February 2015"},{"key":"1906_CR41","unstructured":"UK Chemical Research. Ethylphenidate. https:\/\/www.ukchemicalresearch.org\/Thread-Ethylphenidate?highlight=ethylphenidate . Accessed 13 February 2015"},{"key":"1906_CR42","unstructured":"Personal Power Meditation. Ethylphenidate. http:\/\/www.personalpowermeditation.com\/forum\/drugs\/ethylphenidate\/ . Accessed 13 February 2015"},{"key":"1906_CR43","unstructured":"Bluelight. The Ethylphenidate (Ethyl phenyl(piperidin-2-yl)acetate) Megathread V1. http:\/\/www.bluelight.org\/vb\/archive\/index.php\/t-603365-p-3.html . Accessed 13 February 2015"},{"key":"1906_CR44","unstructured":"Bluelight. The Ethylphenidate (Ethyl phenyl(piperidin-2-yl)acetate) Megathread V2. http:\/\/www.bluelight.org\/vb\/threads\/650058-The-Ethylphenidate-(Ethyl-phenyl(piperidin-2-yl)acetate)-Megathread-V2. Accessed 13 February 2015"},{"key":"1906_CR45","unstructured":"Bluelight. The Ethylphenidate (Ethyl phenyl(piperidin-2-yl)acetate) Megathread V3. http:\/\/www.bluelight.org\/vb\/threads\/687516-The-Ethylphenidate- (Ethyl-phenyl(piperidin-2-yl)acetate)-Megathread-V3. Accessed 13 February 2015"},{"key":"1906_CR46","unstructured":"Drugs-forum. Ethylphenidate experiences. https:\/\/drugs-forum.com\/forum\/showthread.php?t=156994 . Accessed 13 February 2015"},{"key":"1906_CR47","unstructured":"Drugs-forum. Intravenous ethylphenidate: psychosis, dead veins, and deep, necrotic holes. https:\/\/drugs-forum.com\/forum\/showthread.php?t=234933 . Accessed 13 February 2015"},{"key":"1906_CR48","unstructured":"Drugs-forum. Ethylphenidate experience vs methylphenidate experience. https:\/\/drugs-forum.com\/forum\/showthread.php?t=197419 . Accessed 13 February 2015"},{"key":"1906_CR49","unstructured":"Erowid. Erowid experience vaults: ethylphenidate reports. https:\/\/www.erowid.org\/experiences\/subs\/exp_Ethylphenidate.shtml . Accessed 13 February 2015"},{"key":"1906_CR50","unstructured":"Grindfactor. (RCs) Ethylphenidate\u2014anyone have tried this before. http:\/\/www.grindfactor.com\/Forum\/showthread.php?739-ethylphenidate-Anyone-have-tried-this-before . Accessed 13 February 2015"},{"key":"1906_CR51","unstructured":"Reddit. Research chemicals: ethylphenidate experience. http:\/\/www.reddit.com\/r\/researchchemicals\/comments\/2px79m\/ethylphenidate_experience\/ . Accessed 13 February 2015"},{"issue":"8","key":"1906_CR52","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1093\/clinchem\/30.8.1374","volume":"30","author":"BD Potts","year":"1984","unstructured":"Potts BD, Martin CA, Vore M (1984) Gas-chromatographic quantification of methylphenidate in plasma with use of solid-phase extraction and nitrogen-sensitive detection. Clin Chem 30(8):1374\u20131377","journal-title":"Clin Chem"},{"issue":"1","key":"1906_CR53","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1517\/17425247.2.1.121","volume":"2","author":"KS Patrick","year":"2005","unstructured":"Patrick KS, Gonzalez MA, Straughn AB, Markowitz JS (2005) New methylphenidate formulations for the treatment of attention-deficit\/hyperactivity disorder. Expert Opinion on Drug Delivery 2(1):121\u2013143","journal-title":"Expert Opinion on Drug Delivery"},{"issue":"8","key":"1906_CR54","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1021\/jm0490989","volume":"48","author":"KS Patrick","year":"2005","unstructured":"Patrick KS, Williard RL, VanWert AL, et al (2005) Synthesis and pharmacology of ethylphenidate enantiomers: the human transesterification metabolite of methylphenidate and ethanol. J Med Chem 48(8):2876\u20132881. doi: 10.1021\/jm0490989","journal-title":"J Med Chem"},{"issue":"3","key":"1906_CR55","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/sj.clpt.6100082","volume":"81","author":"KS Patrick","year":"2007","unstructured":"Patrick KS, Straughn AB, Minhinnett RR, et al (2007) Influence of ethanol and gender on methylphenidate pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 81(3):346\u2013353","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"1906_CR56","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/FBP.0b013e3280143226","volume":"18","author":"RL Williard","year":"2007","unstructured":"Williard RL, Middaugh LD, Zhu HJ, Patrick KS (2007) Methylphenidate and its ethanol transesterification metabolite ethylphenidate: brain disposition, monoamine transporters and motor activity. Behav Pharmacol 18(1):39\u201351. doi: 10.1097\/FBP.0b013e3280143226","journal-title":"Behav Pharmacol"},{"key":"1906_CR57","doi-asserted-by":"crossref","unstructured":"Bell GH, Novak A, Griffin W, Patrick K (2010) Transdermal dl-methylphenidate potentiates the pharmacokinetic interaction with ethanol relative to oral dosing in a mouse model. FASEB Journal 24(Meeting Abstract Supplement):Ib531.","DOI":"10.1096\/fasebj.24.1_supplement.lb531"},{"key":"1906_CR58","unstructured":"Griffin WC, Bell GH, Novak AJ, et al (2010) Effects of ethanol, methylphenidate, and their combination on conditioned reinforcement and ataxia. Alcohol Clin Exp Res 34(6)"},{"key":"1906_CR59","doi-asserted-by":"crossref","unstructured":"Bell G, Griffin W, Patrick K (2011) Transdermal and oral DL-methylphenidate-ethanol interactions in C57BL\/6J mice: locomotor activity and brain D-, l-methylphenidate and L-ethylphenidate concentrations. FASEB Journal 25(Meeting Abstract Supplement):Ib427.","DOI":"10.1096\/fasebj.25.1_supplement.lb427"},{"issue":"2","key":"1906_CR60","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.pbb.2011.08.026","volume":"100","author":"GH Bell","year":"2011","unstructured":"Bell GH, Griffin 3rd WC, Patrick KS (2011) Oral and transdermal DL-methylphenidate-ethanol interactions in C57BL\/6J mice: potentiation of locomotor activity with oral delivery. Pharmacol Biochem Behav 100(2):264\u2013270. doi: 10.1016\/j.pbb.2011.08.026","journal-title":"Pharmacol Biochem Behav"},{"key":"1906_CR61","doi-asserted-by":"crossref","unstructured":"Padala P, Padala K, Petty F, Burke W (2011) Randomized controlled trial for treatment of apathy in Alzheimer\u2019s disease. Alzheimer\u2019s and Dementia 7(4 SUPPL. 1).","DOI":"10.1016\/j.jalz.2011.05.872"},{"key":"1906_CR62","unstructured":"Reeves O, Straughn A, Bell G, et al (2011) Ethanol elevates plasma dexmethylphenidate and dl-methylphenidate concentrations and potentiates subjective effects. J Clin Pharmacol 51(9)"},{"issue":"11\u201312","key":"1906_CR63","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.jchromb.2011.02.033","volume":"879","author":"HJ Zhu","year":"2011","unstructured":"Zhu HJ, Patrick KS, Markowitz JS (2011) Enantiospecific determination of dl-methylphenidate and dl-ethylphenidate in plasma by liquid chromatography-tandem mass spectrometry: application to human ethanol interactions. J Chromatogr B Anal Technol Biomed Life Sci 879(11\u201312):783\u2013788","journal-title":"J Chromatogr B Anal Technol Biomed Life Sci"},{"issue":"3","key":"1906_CR64","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00213-012-2849-z","volume":"225","author":"IIIWC Griffin","year":"2013","unstructured":"Griffin IIIWC, McGovern RW, Bell GH, et al (2013) Interactive effects of methylphenidate and alcohol on discrimination, conditioned place preference and motor coordination in C57BL\/6J mice. Psychopharmacology 225(3):613\u2013625","journal-title":"Psychopharmacology"},{"issue":"1","key":"1906_CR65","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1124\/dmd.112.048595","volume":"41","author":"KS Patrick","year":"2013","unstructured":"Patrick KS, Straughn AB, Reeves IIIOT, et al (2013) Differential influences of ethanol on early exposure to racemic methylphenidate compared with dexmethylphenidate in humans. Drug Metab Dispos 41(1):197\u2013205","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"1906_CR66","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.toxlet.2014.10.026","volume":"232","author":"MR Meyer","year":"2015","unstructured":"Meyer MR, Schutz A, Maurer HH (2015) Contribution of human esterases to the metabolism of selected drugs of abuse. Toxicol Lett 232(1):159\u2013166","journal-title":"Toxicol Lett"},{"key":"1906_CR67","unstructured":"Home Office (2012) Annual Report on the Home Office Forensic Early Warning System (FEWS): a system to identify new psychoactive substances in the UK. https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/98031\/fews.pdf . Accessed 30 June 2015"},{"key":"1906_CR68","unstructured":"Home Office. The Misuse of Drugs Act 1971 (Temporary Class Drug) Order 2015. http:\/\/www.legislation.gov.uk\/uksi\/2015\/1027\/pdfs\/uksi_20151027_en.pdf . Accessed 30 June 2015"},{"key":"1906_CR69","unstructured":"Ministry of Health, Germany (2013) Siebenundzwanzigste Verordnung zur \u00c4nderung bet\u00e4ubungsmittel-rechtlicher Vorschriften (Twenty-Seventh Regulation amendment of the Narcotics Legislation). http:\/\/www.bundesgesundheitsministerium.de\/fileadmin\/dateien\/Downloads\/B\/Betaeubungsmittelgesetz\/27_BtMAEndV.pdf . Accessed 30 June 2015"},{"key":"1906_CR70","unstructured":"Ministry of Health, Denmark (2013) Bekendtg\u00f8relse om \u00e6ndring af bekendtg\u00f8relse om euforiserende stoffer (Order amending the Order on drugs). https:\/\/www.retsinformation.dk\/pdfPrint.aspx?id=145195 . Accessed 30 June 2015"},{"key":"1906_CR71","unstructured":"Ministry of Social Affairs, Sweden. F\u00f6rordning (1992:1554) om kontroll av narkotika (Regulation (1992: 1554) on control of narcotics). http:\/\/www.riksdagen.se\/sv\/Dokument-Lagar\/Lagar\/Svenskforfattningssamling\/Forordning-19921554-om-kont_sfs-1992-1554\/?bet=1992:1554 . Accessed 30 June 2015"},{"issue":"7","key":"1906_CR72","doi-asserted-by":"crossref","first-page":"678","DOI":"10.3109\/15563650.2014.933346","volume":"52","author":"AE Vermette-Marcotte","year":"2014","unstructured":"Vermette-Marcotte AE, Dargan PI, Archer JR, Gosselin S, Wood DM (2014) An Internet snapshot study to compare the international availability of the novel psychoactive substance methiopropamine. Clin Toxicol (Phila) 52(7):678\u2013681. doi: 10.3109\/15563650.2014.933346","journal-title":"Clin Toxicol (Phila)"},{"issue":"1","key":"1906_CR73","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3109\/15563650.2014.983239","volume":"53","author":"S Siddiqi","year":"2015","unstructured":"Siddiqi S, Verney C, Dargan P, Wood DM (2015) Understanding the availability, prevalence of use, desired effects, acute toxicity and dependence potential of the novel opioid MT-45. Clin Toxicol (Phila) 53(1):54\u201359. doi: 10.3109\/15563650.2014.983239","journal-title":"Clin Toxicol (Phila)"},{"key":"1906_CR74","doi-asserted-by":"crossref","unstructured":"Nizar H, Dargan P, Wood D (2014) Using Internet snapshot surveys to enhance our understanding of the availability of the novel psychoactive substance 4-methylaminorex and 4,4\u2032-dimethylaminorex. J Med Toxicol. doi: 10.1007\/s13181-014-0425-0","DOI":"10.1007\/s13181-014-0425-0"},{"key":"1906_CR75","unstructured":"FBI. Cyber crime: purchase order scam leaves a trail of victims. https:\/\/www.fbi.gov\/news\/stories\/2014\/october\/cyber-crime-purchase-order-scam-leaves-a-trail-of-victims\/cyber-crime-purchase-order-scam-leaves-a-trail-of-victims . Accessed June 30 2015"},{"key":"1906_CR76","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1477-7517-11-25","volume":"11","author":"C Soussan","year":"2014","unstructured":"Soussan C, Kjellgren A (2014) Harm reduction and knowledge exchange\u2014a qualitative analysis of drug-related Internet discussion forums. Harm Reduct J 11:25. doi: 10.1186\/1477-7517-11-25","journal-title":"Harm Reduct J"},{"key":"1906_CR77","unstructured":"news.com.au. Darknet vendors are using an \u2018exit scam\u2019 to fraud potential customers http:\/\/www.news.com.au\/technology\/online\/darknet-vendors-are-using-an-exit-scam-to-fraud-potential-customers\/story-fnjwmwrh-1227211244649 . Accessed 30 June 2015"},{"key":"1906_CR78","author":"DM Wood","year":"2013","unstructured":"Wood DM, Dargan PI (2013) Using Internet snapshot surveys to enhance our understanding of the availability of the novel psychoactive substance alpha-methyltryptamine (AMT). Subst Use Misuse. doi: 10.3109\/10826084.2013.808224","journal-title":"Subst Use Misuse"},{"key":"1906_CR79","first-page":"191","volume":"7","author":"A Kjellgren","year":"2013","unstructured":"Kjellgren A, Henningsson H, Soussan C (2013) Fascination and social togetherness\u2014discussions about Spice smoking on a Swedish Internet forum. Subst Abuse 7:191\u2013198. doi: 10.4137\/SART.S13323","journal-title":"Subst Abuse"},{"issue":"3","key":"1906_CR80","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1080\/02791072.2013.803647","volume":"45","author":"A Kjellgren","year":"2013","unstructured":"Kjellgren A, Jonsson K (2013) Methoxetamine (MXE)\u2014a phenomenological study of experiences induced by a \u201clegal high\u201d from the Internet. J Psychoactive Drugs 45(3):276\u2013286. doi: 10.1080\/02791072.2013.803647","journal-title":"J Psychoactive Drugs"},{"issue":"2","key":"1906_CR81","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/BF00280074","volume":"40","author":"C Fracasso","year":"1991","unstructured":"Fracasso C, Confalonieri S, Garattini S, Caccia S (1991) Single and multiple dose pharmacokinetics of etizolam in healthy subjects. Eur J Clin Pharmacol 40(2):181\u2013185","journal-title":"Eur J Clin Pharmacol"},{"key":"1906_CR82","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.neuropharm.2012.06.016","volume":"64","author":"CI Ragan","year":"2013","unstructured":"Ragan CI, Bard I, Singh I, Independent Scientific Committee on D (2013) What should we do about student use of cognitive enhancers? An analysis of current evidence. Neuropharmacology 64:588\u2013595. doi: 10.1016\/j.neuropharm.2012.06.016","journal-title":"Neuropharmacology"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-015-1906-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-015-1906-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-015-1906-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T13:33:32Z","timestamp":1748525612000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-015-1906-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,22]]},"references-count":82,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["1906"],"URL":"https:\/\/doi.org\/10.1007\/s00228-015-1906-z","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,22]]}}}